Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain
This article was originally published in The Pink Sheet Daily
Executive Summary
Even after paying BioMarin $67.5 million for the voucher itself, the firms still don’t know how much FDA will charge for a chance to get Praluent to market faster.